Medications

Drug maker Novartis loses India patent battle (Update)

India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued ...

Other

COI declarations and off-label drug use

Conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, ...

Diseases, Conditions, Syndromes

Drugmaker Glaxo shuts down plant over Legionnaires' bacteria

Drugmaker GlaxoSmithKline shut down a plant Tuesday that produces inhaled medications after discovering the bacteria that causes Legionnaire's disease, a potentially fatal form of pneumonia.

Medications

S.Africa tackles drugs patent reform

South Africa's government has published a draft intellectual property policy with potential far-reaching effects for pharmaceutical patents, which rights groups hailed Monday as a move towards lower medicine costs.

Medications

Vandetanib in thyroid cancer: Added benefit not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute ...

Oncology & Cancer

Added benefit of ingenol mebutate is not proven

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act ...

Medications

Aflibercept in AMD: No proof of added benefit

It is not proven that patients with wet age-related macular degeneration benefit from the new drug aflibercept, as the drug manufacturer did not present any suitable data for a comparison with the current standard therapy ...

page 2 from 4